State of the evidence: The connection between breast cancer and the environment

International Journal of Occupational and Environmental Health

Volumn 15, Issue 1, 2009, Pages 43-78

  Gray, Janet ^a   Evans, Nancy ^b   Taylor, Brynn ^c   Rizzo, Jeanne ^b   Walker, Marisa ^b  

^a VASSAR COLLEGE   (United States)

^b Breast Cancer Fund   (United States)

^c NONE

Author keywords

Breast cancer; Endocrine disruptors; Radiation

Indexed keywords

BREAST TUMOR; DANGEROUS GOODS; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; INCIDENCE; REVIEW;

BREAST NEOPLASMS; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; FEMALE; HAZARDOUS SUBSTANCES; HUMANS; INCIDENCE;

EID: 65249155440     PISSN: 10773525     EISSN: None     Source Type: Journal    
DOI: 10.1179/oeh.2009.15.1.43     Document Type: Review

References (438)

1. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med. 2006;84:16-28.
2. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004;6: 213-18.
3. Michels KB, Mohllajee AP, Roset-Bahmanyar ER, et al. Diet and breast cancer. Cancer 2007;109(S12):2712-49
4. Zheng SM, Lee I-M, Manson JE, et al. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol. 2007;165:667-76.
5. Visvanathan K, Crum RM, Strickland PT, et al. Alcohol dehydrogenase genetic polymorphisms, low-to-moderate alcohol consumption, and risk of breast cancer. Alcohol: Clin Exp Res. 2007;31:467-76.
6. Monninkhof EM, Elias SG, Vlems FA, et al. Physical activity and breast cancer: a systematic review. Epidemiology. 2007;18:137-57.
7. Kruk J, Aboul-Enein HY. Environmental exposure, and other behavioral risk factors in breast cancer. Curr Cancer Ther Rev. 2006;2:3-21.
8. Cutler SJ, Connelly, RR. Mammary cancer trends. Cancer. 1969;23:767-71.
9. Jatoi I, Anderson WF, Rao SR, Devesa SS. Breast cancer trends among black and white women in the United States. J Clin Oncol. 2005;23:7836-41.
10. Ries LAG, Melbert D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2004. Bethesda (MD): National Cancer Institute; [Internet]. 2006 Nov. Available from: www.seer.cancer.gov/csr/1975-2004
11. Jemal A, Siegel E, Ward E, et al. Cancer statistics: 2006. CA: Cancer J Clin. 2006;56:106-30.
12. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Result (SEER) Program. Oncologist. 2007;12:20-37.
13. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in incidence in breast cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670-74.
14. Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99:1152-61.
15. Centers for Disease Control and Prevention (CDC). Decline in breast cancer incidence United States, 1999-2003. Morbidity and Mortality Weekly Report. 2007;56:549-53.
16. Robbins AS Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol. 2007;25:3437-9.
17. Colditz GA. Decline in breast cancer inidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res. 2007;9:108.
18. In this report we have chosen to use the terms for various racial and ethnic groups that have been used by the authors of particular papers we are citing. We recognize the complexity, and perhaps inappropriateness, of using simple names to categorize richly diverse groups of people who are clustered together somewhat arbitrarily because of their biological, social or cultural histories. Yet we also believe it is important to cite and discuss the growing scientific literature demonstrating disparities in exposures and responses to exposures across different racially and ethnically designated groups.
19. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA: Cancer J Clin. 2006;56:168-83.
20. Bowen RL, Stebbing J, Jones LJ. A review of the ethnic differences in breast cancer. Pharmacogenomics. 2006;7:935-42.21.
21. Jones BA, Kasl SV, Howe CL, et al. African American/White differences in breast cancer carcinoma. Cancer. 2004;101:1293-1301.
22. National Center for Health Statistics. Health, United States, 2006: chartbook on trends in the health of Americans [Internet]. 2006; Available from www.cdc.gov/nchs/data/hus/hus06.pdf
23. Parkin DM, Fernandez, LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006;12(Suppl 1):S70-S80.
24. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: Cancer J Clin. 2005;55:74-108.
25. Boffetta P, Parkin DM. Cancer in developing countries. CA: Cancer J Clin. 1994;44:81-90.
26. Althuis MD, Dozier JM, Anderson WF, et al. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005;34:405-12.
27. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian American women. J Natl Cancer Inst. 1993;85(22):1819-27.
28. Stanford JL, Herrinton LJ, Schwartz SM, Weiss NS. Breast cancer incidence in Asian migrants to the United States and their descendants. Epidemiology. 1995;6:181-3.
29. John EM, Phipps AI, Koo J. Migration history, acculturation, and breast cancer risk in Hispanic women. Cancer Epidemiol Biomarkers Prev. 2005;14: 2905-13.
30. Hemminki K, Li X. Cancer risks in second-generation immigrants to Sweden. Int J Cancer. 2002;99:229-37.
31. Andreeva VA, Unger JB, Pentz MA. Breast caner among immigrants; A systematic review and new research directions. J Immigrant Minority Health. 2007;9:307-322.
32. Birnbaum LS, Fenton SE. Cancer and developmental exposure to endocrine disruptors. Environ Health Persp. 2003;111:389-94.
33. Sasco A. Epidemiology of breast cancer: An environmental disease? APMIS. 2001;109:321-32.
34. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302: 643-46.
35. Simchoni S, Friedman E, Kaufman B, et al. Familial clustering of site-specific cancer risks associated with BRCA1and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci. 2006;103: 3770-74.
36. Kroiss R, Winkler V, Bikas D, et al. Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers. Hum Mut. 2005;26:583-9.
37. Lichtenstein P, Niels V, Pia K. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med. 2000;343(2):78-85.
38. Baker SG, Lichtenstein P, Kaprio J, Holm N. Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins. Biometrics. 2005;61:55-63.
39. Czene K, Lichtenberg P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family cancer database. Int J Cancer. 2002;99;260-66.
40. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007;129:1065-79.
41. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide susceptibility study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-1093.
42. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39(7):870-4.
43. Zuo T, Wang L, Morrison C, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007;29;129(7):1275-86.
44. American Cancer Society. Cancer facts and figures 2007. Atlanta, GA: American Cancer Society, Inc.
45. Newman LA. Breast cancer in African American women. Oncologist. 2005;10:1-14.
46. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc. 2006;295:2492-2502.
47. Swanson GM, Haslam SZ, Azzouz F. Breast cancer among young African American women. Cancer Suppl. 2003;97:273-79.
48. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966-75.
49. Palmer JB, Wise LA, Horton NJ, et al. Dual effect of parity on breast cancer risk in African American women. J Natl Cancer Inst. 2003;95:478-83.
50. Jernstrom H, Chu W, Vesprini D, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab. 2001;72:144-54.
51. Centers for Disease Control and Prevention. Third National Report on Human Exposure to Environmental Chemicals. Atlanta (GA): CDC, 2005.
52. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721-28.
53. Mills PK, Yang R. Breast cancer risk in Hispanic agricultural workers in California. Int J Occup Environ Health. 2005;11:123-31.
54. Li R, Gilliland FD, Baumgartner K, Samet J. Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women. Cancer. 2002;95:960-68.
55. Ely B, Wilson JL, Jackson F, Jackson BA. African-American mitochondrial DNAs often match mtDNAs found in multiple African ethnic groups. BMC Biol. 2006;4:34.
56. Paltoo DN, Chu KC. Patterns in cancer incidence among American Indians/Alaska Natives, United States, 1992-1999. Pub Health Rep. 2004;119:443-51.
57. Deapen D, Liu L, Perkins C, et al. Rapidly rising breast cancer incidence rates among Asian American women. Int J Cancer. 2002;99:747-50.
58. Environmental Protection Agency, Office of Pollution Prevention and Toxics. Overview: Office of Pollution Prevention and Toxics Programs [Internet]. 2007 Oct 8. Available from: www.epa.gov/oppt/pubs/oppt101c2.pdf , October 8, 2007.
59. Bennett M, Davis BJ. The identification of mammary carcinogens in rodent bioassays. Environ Mol Mut. 2002;39(2-3):150-7.
60. Brody JG, Moysich KB, Humblet O, et al. Environmental pollutants and breast cancer: epidemiologic studies. Cancer. 2007;109(Suppl 12):2667-711.
61. Rudel RA, Attfield KA, Schifano JN, Brody JG. Chemicals causing mammary gland tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention. Cancer. 2007;109(Suppl 12):2635-66.
62. Rudel RA, Camann DE, Spengler JD, et al. Phthalates, alkylphenols, pesticides, polybrominated diphenyl ethers, and other endocrine-disrupting compounds in air and dust. Environ Sci Technol. 2003;37: 4543-53.
63. Siddiqui MK, Anand M, Mehrotra PK, et al. Biomonitoring of organochlorines in women with benign and malignant breast disease. Environ Res. 2004;98:250-7.
64. Nickerson K. Environmental contaminants in breast milk. J Midwifery Women's Health. 2006;51:26-34.
65. Dunnick JK, Elwell MR, Huff J, Barrett JC. Chemically induced mammary gland cancer in the National Toxicology Program's carcinogenesis bioassay. Carcinogenesis. 1995;16:173-9.
66. Wolff MS, Teitelbaum SL, Windham G, et al. Pilot study of urinary biomarkers of phytoestrogens, phthalates, and phenols, in girls. Environ Health Persp. 2007;115:116-21.
67. Shen H, Main KM, Virtanen HE, et al. From mother to child: Investigation of prenatal and postnatal exposure to persistent bioaccumulating toxicants using breast milk and placenta biomonitoring. Chemosphere. 2007;67:S236-S262.
68. Chen JW, Wang SL, Yu HY, et al. Body burden of dioxins and dioxin-like polychlorinated biphenyls in pregnant women residing in a contaminated area. Chemosphere. 2006;65:1667-77.
69. Anderson HA, Wolff MS. Environmental contaminants in human milk. J Expo Anal Environ Epidemiol. 2000;10(II Suppl.):755-60.
70. Van der Ven K, Van der Ven H, Thibold A, et al. Chlorinated hydrocarbon content of fetal and maternal body tissues and fluids in full term pregnant women: a comparison of Germany and Tanzania. Hum Reprod. 1992;7(Suppl. 1):95-100.
71. Carpenter DO, Arcaro KF, Bush B, et al. Human health and chemical mixtures: An overview. Environ Health Persp. 1998;106(Suppl 6):1263-70.
72. Kortenkamp A. Breast cancer, oestrogens and environmental pollutants: a re-evaluation from a mixture perspective. Int J Androl. 2006;29:193-8.
73. Koppe JG, Bartonova A, Bolte G, et al. Exposure to multiple environmental agents and their effect. Acta Ped. 2006;95(Suppl 453):106-13.
74. Ramamoorthy K, Wang F, Chen IC, et al. Potency of combined estrogenic pesticides. Science. 1997;275:405-6.
75. Arnold SF, Klotz DM, Collins BM et al. Synergistic activation of estrogen receptor with combinations of environmental chemicals. Science. 1996;272:1489-92.
76. Xie L, Thrippleton K, Irwin MA, et al. Evaluation of estrogenic activities of aquatic herbicides and surfactants using a rainbow trout vitellogenin assay. Toxicol Sci. 2005;87:391-8.
77. Payne J, Rajapakse N, Wilkins M, et al. Prediction and assessment of the effects of mixtures of four xenoestrogens. Environ Health Perspect 2000;108:983-7.
78. Rajapakse N, Silva E, Kortenkamp A. Combining xenoestrogens at levels below individual no-observed-effect concentrations dramatically enhances steroid hormone action. Environ Health Persp. 2002;110:917-21.
79. Rajapakse N, Ong D, Kortenkamp A. Defining the impact of weakly estrogenic chemicals on the action of steroidal chemicals. Toxicol Sci. 2001;60:296-304.
80. Russo J, Russo I. The role of estrogen in breast cancer. In: Molecular basis of breast cancer. Berlin: Springer-Verlag; 2004. Chapter 4: p 89-136.
81. Foster WG, Younglai EV, Boutross-Tadross O, et al. Mammary gland morphology in Sprague-Dawley rats following treatment with an organochlorine mixture in utero and neonatal genistein. Toxicol Sci. 2004;77:91-100.
82. Imaoka T, Nishimura M, Teramoto A, et al. Cooperative induction of rat mammary cancer by radiation and 1-methyl-1-nitrosurea via the oncogenic pathways involving c-Myc activation and H-ras mutation. Int J Cancer. 2005;115:187-93.
83. Millikan R, DeVoto E, Duell EJ, et al. Dichloro-diphenyldichloroethene, polychlorinated biphenyls and breast cancer among African-American and white women in North Carolina. Cancer Epidemiol Biomarkers Prev. 2000;9:1233-40.
84. Laden F, Ishibe N, Hankinson SE, et al. Polychlorinated biphenyls, cytochrome P450 1A1, and breast cancer risk in the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev. 2002;11:1560-5.
85. Olivier M, Hainaut P. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Sem Cancer Biol. 2001;11:353-60.
86. Calabrese EJ. Hormesis: from marginalization to mainstream: a case for hormesis as the default dose-response model in risk assessment. Toxicol App Pharmacol. 2004;197:125-36.
87. Fenton SE. Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences. Endocrinology. 2006;147(Suppl):S18- S24.
88. Russo J, Hu YF, Silva ID, Russo IH. Cancer risk related to mammary gland structure and development. Microsc Res Tech. 2001;52:204-23.
89. Guisti RM, Iwamoto K, Hatch EE. Diethystilbestrol revisited: a review of the long-term health effects. Ann Intern Med. 1995;122:778-88.
90. Li S, Hursting SD, Davis BJ, et al. Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbestrol-induced cancers. Ann NY Acad Sci. 2003;983:161-9.
91. Colton T, Greenberg ER, Noller K, et al. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy: further followup. J Am Med Assoc. 1993;269:2096-2100.
92. Titus-Ernstoff L, Hatch EE, Hoover RN, et al. Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy. Brit J Cancer. 2001. 84: 126-133.
93. Troisi R, Hatch EE, Titus-Ernstoff L, et al. Cancer risk in women prenatally exposed to diethylstilbestrol. Int J Cancer. 2007;121:356-60.
94. Hilakivi-Clarke L, de Assis S. Fetal origins of breast cancer. Trends Endocrinol Metab. 2006;17:340-8.
95. Roseboom T, de Rooij S, Painter R. The Dutch famine and its long-term consequences for adult health. Early Hum Dev. 2006;82:485-91.
96. Santodonato J. Review of the estrogenic and antiestrogenic activity of polycyclic aromatic hydrocarbons: relationship to carcinogenicity. Chemosphere. 1997;34:835-48.
97. Bonner MR, Han D, Nie J, et al. Breast cancer risk and exposure in early life to polycyclic aromatic hydrocarbons using total suspended particulates as a proxy measure. Cancer Epidemiol Biomarkers Prev. 2005;14:53-60.
98. Calafat AM, Kuklenyik Z, Reidy JA, et al. Urinary concentrations of bisphenol A and 4-nonyphenol in a human reference population. Environ Health Persp. 2005;113:391-5.
99. Munoz-de-Toro M, Markey C, Perinaaz RW, et al. Perinatal exposure to bisphenol A alters peripubertal mammary gland development in mice. Endocrinology. 2005;146:4138-47.
100. Vandenberg LN, Maffini MV, Wadia PR, et al. Exposure to environmentally relevant doses of the xenoestrogen bisphenol-A alters development of the fetal mouse mammary gland. Endocrinology. 2007;148:116-27.
101. Markey CM, Luque EH, Munoz-de-Toro MM, et al. In utero exposure to bisphenol A alters the development and tissue organization of the mouse mammary gland. Biol Reprod. 2001;65:1215-23.
102. Murray TJ, Maffini MV, Ucci AA, et al. Induction of mammary gland ductal hyperplasias and carcinoma in situ following fetal bisphenol A exposure. Reprod Toxicol. 2007;23:383-90.
103. Brown NM, Manzolillo PA, Zhang J-H, et al. Prenatal TCCD and predisposition to mammary cancer in the rat. Carcinogenesis. 1998;1:1623-9.
104. Fenton SE, Hamm JT, Birnbaum LA, Youngblood GL. Persistent abnormalities in the rat mammary gland following gestational and lactational exposure to 2,3,7,8-tetrachlorodibenzopdioxin (TCDD). Toxicol Sci. 2002;67:63-74.
105. Jenkins S, Rowell C, Wang J, Lamartiniere. Prenatal TCDD exposure predisposes for mammary cancer in rats. Reprod Toxicol. 2007;23:391-6.
106. Enoch RR, Stanko JP, Greiner SN, et al. Mammary gland development as a sensitive endpoint after acute prenatal exposure to an atrazine metabolite mixture in female Long Evans rats. Environ Health Persp. 2007;115:5541-7. Atlanta: American Cancer Society, Inc
107. Cohn BA, Wolff MA, Cirillo PM, Sholtz RI. DDT and breast cancer in young women: new data on the significance of age at exposure. Environ Health Persp. 2007;115:1406-14.
108. Boice, JD. Radiation and breast carcinogenesis. Med Ped Oncol. 2001;26:508-13.
109. Preston DL, Mattsson A, Holmberg E, et al. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158:220-35.
110. Tokunaga M, Land CE, Tokuoka S, et al. Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiat Res. 1994;138:209-23.
111. Land CE, Tokunaga M, Koyama et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res. 2003;160:707-717.
112. Pukkala E, Kesminiene A, Poliakov S, et al. Breast cancer in Belarus and Ukraine aafter the Chernobyl accident. Int J Cancer. 2006;119:651-8.
113. Morin-Doody M, Lonstein JE, Stovall M, et al. Breast cancer mortality after diagnostic radiography: findings from the U.S. Scoliosis Cohort Study. Spine. 2000;25:2052-63.
114. Clemons MM, Loijens L, and Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 2000;26:291-300.
115. Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of Non-Hodgkin's Lymphoma. Cancer. 2006;107:108-15.
116. Howe GR, McLaughlin J. Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study. Radiat Res. 1996;145:694-707.
117. Hildreth NG, Shore RE, Dvoretsky PM. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med. 1989;321:1281-4.
118. Ma H. Hill CK, Bernstein L, Ursin G. Low-dose medical radiation exposure and breast cancer risk in women under age 50 years overall and by estrogen and progesterone status: results from a case-control and a case-case study. Breast Cancer Res Treat. 2008:109:77-90.
119. Baer HJ, Schnitt SJ , Connolly JL, et al. Adolescent diet and incidence of proliferative benign breast disease. Cancer Epidemiol, Biomarkers Prev. 2003;12:1159-67.
120. Frazier AL, Ryan CT, Rockett H, et al. Adolescent diet and risk of breast cancer. Breast Cancer Res. 2003;5:R59-R64.
121. Murrill WB, Brown NM, Zhang JX, et al. Prepubertal genestein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis. 1996;17:1451-7.
122. Wu AH, Wan P, Hankin J, et al. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis. 2002;23:1491-6.
123. Lagerros YT, Hsieh SF, Hsieh CC. Physical activity in adolescence and young adulthood and breast cancer risk: a quantitative review. Eur J Cancer Prev. 2004;13:5-22.
124. Love S. What kind of cancer is it? In: Dr. Susan Love's breast book. 4th ed. Cambridge (MA): Perseus Publishing; 2005. Chapter 20: p. 260-280.
125. Daewood S, Cristofamilli M. What progress have we made in managing inflammatory breast cancer? (Disease/disorder overview). Oncology. 2007;21:673-85.
126. Mokbel K, Cutuli B. Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet Oncol. 2006;7:756-65.
127. Hansen J. Elevated risk for male breast cancer after occupational exposure to gasoline and vehicular combustion products. Am J Ind Med. 2000;37:349-52.
128. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-52.
129. Palli D, Masala G, Mariani-Costanini R, et al. A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer? Eur J Cancer. 2004;40:2474-9.
130. Sørlie T, Tibshirani Parker RJ, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U.S.A. 2003;100:8418-23.
131. Carey LA, Perou CM, Livasy CA, et al. The poor prognosis basal-like breast cancer subtype is over-represented in young African-American women. J Am Med Assoc. 2006;7:2492-502.
132. Ying MWL, Agrawal A, Cheung KL. The 'other half' of breast cancer: a review of male breast cancer. J Men's Health Gender. 2005;2:406-14.
133. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:20-26.
134. De los Santos JF, Buchholz TA. Carcinogenesis of the male breast. Curr Treat Options Oncol. 2000;1:221-7.
135. Honma N, Takubo K, Sawabe M, et al. Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. J Clin Endocrinol Metab. 2007;91:607-13.
136. International Agency for Research on Cancer. IARC Monographs. 1987;(Suppl 7):280.
137. National Toxicology Program. Tenth report on carcinogens. Research Triangle Park.:National Institute of Environmental Health Sciences, National Institutes of Health, 2002.
138. Krieger N, Löwy I, Aronowitz R, Bigby J, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. Journal of Epidemiology and Community Health. 2005;59:740-8.
139. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713-27.
140. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-59.
141. International Agency for Research on Cancer. Hormonal contraception and postmenopausal hormonal therapy. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 72. Lyon: IARC 1999.
142. Brinton LA, Brogan DR, Coates RJ, et al. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause. 1998;5(3):145-51.
143. Lund E, Bakken K, Dumeaux V, et al. Hormone replacement therapy and breast cancer in former users of oral contraceptives: the Norwegian women and cancer study. Int J Cancer. 2007;121:645-8.
144. Shantakumar S, Terry MB, Paykin A, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol. 2007;165:1187-98.
145. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc. 2002;288(3):321-33.
146. Anderson GL, Limacher M. Effects of conjugated equine estrogen in postmenopausal women with hysteresctomy: The Women's Health Initiative randomized controlled study. J Am Med Assoc. 2004;291:1701-12.
147. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?): trial stopped. Lancet. 2004;363:453-5.
148. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-27.
149. Borgquist S, Anagnostaki L, Jirstom K, et al. Breast tumours following combined hormone replacement therapy express favorable prognostic factors. Int J Cancer. 2007;120: 2202-7.
150. Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2006;7:910-18.
151. Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. American Journal of Obstetrics & Gynecology. 2007;196:e1-9.
152. Kumle M, Weiderpass E, Braaten T, et al. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev. 2002;11:1375-81.
153. Althuis MD, Brogan DD, Coates RJ, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control. 2003;14:151-60.
154. Deligeroroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. Annals Ann NY Acad Sci. 2003;997:199-208.
155. Newcomer LM, Newcomb PA, Trentham-Dietz A, et al. Oral contraceptive use and risk of breast cancer by histologic type. Int J Cancer. 2003;106:961-4.
156. Delort L, Kwiatkowski F, Chalabi N, et al. Risk factors for early age at breast cancer onset: the "COSA Program" population based study. Anticancer Res. 2007;27:1087-94.
157. Grabrick DM, Hartmann LC, Cerhan RJ, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. J Am Med Assoc. 2000;284:1791-8.
158. Narod SA, Dube MP, Klign J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94:1773-9.
159. Haile RW, Thomas DC, McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev. 2006;15:1863-70.
160. Sweeney C, Giuliano AR, Baumgartner KB, et al. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. Int J Cancer 2007;121:2517-2523.
161. Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence: a report of seven cases including six clear cell carcinomas (so-called mesonephromas). Cancer. 1970;25:745-57.
162. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284:878-81.
163. Bibbo M, Gill WB, Azizi F, et al. Follow-up study of male and female offspring of DES-exposed mothers. Obstet Gynecol J. 1977;49:1-8.
164. Palmer JR, Wise LA, Hatch EE, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:1509-14.
165. Tiwary CM. Premature sexual development in children following the use of estrogen-or placenta-containing hair products. Clin Ped. 1998;27:733-9.
166. Tiwary CM, Ward JA. Use of hair products containing hormone or placenta by U.S. military personnel. J Ped Endocrinol Metab. 2003;16:1025-32.
167. Li ST, Lozano P, Grossman DC, Graham E. Hormone-containing hair product use in prepubertal children. Arch Ped Adol Med. 2002;156:85-6.
168. Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasi S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer. 2002;46:796-800.
169. Donovan M, Tiwary CM, Axelrod D, et al. Personal care products that contain estrogens or xenoestrogens may increase breast cancer risk. Med Hypoth. 2007;68:756-66.
170. Rice S, Whitehead SA. Phytoestrogens and breast cancer: promoters or protectors? Endoc Relat Cancer. 2006;13:995-1015.
171. Jaga K, Duvvi H. Risk reduction for DDT toxicity and carcinogenesis through dietary modification. Journal of the Royal Society for the Promotion of Health. 2001;121:107-13.
172. Adlercreutz H. Phytoestrogens and breast cancer. J Steroid Biochem Mol Biol. 2003;83:113-18.
173. Murata M, Midorikawa K, Koh M, et al. Genistein and daidzein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs. Biochemistry. 2004;43:2569-77.
174. Liu B, Edgerton S, Yang X, et al. Low dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res. 2005;65:879-86.
175. Constantinou AI, White BE, Tonetti D, et al. The soy isoflavone daidezein improves the capacity of tamoxifen to prevent mammary tumors. Eur J Cancer. 2005;41:647-54.
176. National Research Council. Effects on reproduction and development.. In: Hormonally Active Agents in the Environment. Washington: National Academy of Sciences; 1999. Chapter 5, p 119-170.
177. Erickson BE. Tests of endocrine disruptors delayed. Chem Eng News 2008;86:60-2.
178. Davis DL, Bradlow HL, Wolff M, et al. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ Health Persp. 1993;101(5):371-7.
179. Soto AM, Justicia H, Wray JW, Sonnenschein C. p-Nonylphenol: An estrogenic xenobiotic released from "modified" polystyrene. Environ Health Persp. 1991;92:167-73.
180. Soto AM , Chung KL, Sonnenschein C. The pesticides endosulfan, toxaphene, and dieldrin have estrogenic effects on human estrogen-sensitive cells. Environ Health Persp. 1994;102:380-3.
181. Commission of the European Communities. Commission staff working document on implementation of the community strategy for endocrine disruptors: a range of substances suspected of interfering with the hormone systems of humans and wildlife [Internet]. 2004. Available from: ec.europa.eu/environment/endocrine/ documents/sec-2004-1372-en.pdf
182. Brody JG, Rudel RA, Melly SJ, Maxwell NI. Endocrine disruptors and breast cancer. For Appl Res Public Pol. 1998;13(3):24-31.
183. McKelvey W, Brody JG, Aschengrau A, Swartz CH. Association between residence on Cape Cod, Massachusetts, and breast cancer. Ann Epidemiol. 2004;14:89-94.
184. Rudel RA, Geno P, Melly SJ, et al. Identification of alkylphenols and other estrogenic phenolic compounds in wastewater, septage, and groundwater on Cape Cod, Massachusetts. Environ Sci Technol. 1998;32(7):861-9.
185. Kulkarni PS, Crespo JG, Afonso CAM. Dioxin sources and current remediation technologies-A review. Environ Int. 2008:34:139-153.
186. IARC (International Agency for Research on Cancer) 1997. Polychlorinated Dibenzo-para-dioxins and Polychlorinated Dibenzofurans. IARC Monogr Eval Carcinog Risks Hum 69.
187. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Chlorinated Dibenzo-p-Dioxins. Public Health Service, U.S. Department of Health and Human Services, Atlanta, GA. 1998.
188. Schecter A, Birnbaum L, Rryan JJ, Constable JD. Dioxins: An overview. Environ Res. 2006:101:419-426.
189. Massart F, Harrell JC, Federico G, et al. Human breast milk and xenoestrogen exposure: A possible impact on human health. J Perinatol. 2005;25:282-8.
190. Warner MB, Eskenazi B, Mocarelli P, et al. Serum dioxin concentrations and breast cancer risk in the Seveso Women's Health Study. Environ Health Persp. 2002;110:625-8.
191. Manz A, Berger J, Dwyer JH, et al. Cancer mortality among workers in chemical plant contaminated with dioxin. Lancet. 1991;338:959-64.
192. Lewis BC, Hudgins S, Lewis A, et al. In utero and lactational treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin impairs mammary gland differentiation but does not block the response to exogenous estrogen in the postpubertal rat. Toxicological Science. 2001;62:63-74.
193. Simcox NJ, Fenske RA, Wolz SA, et al. Pesticides in household dust and soil: exposure pathways for children of agricultural families. Environ Health Persp. 1995;103:1126-34.
194. Beard J. DDT and human health. Sci Total Environ. 2006;355:78-89.
195. World Health Organization Roll Back Malaria Partnership. Final DDT agreement endorses RBM objectives. Roll Back Malaria News 3 [Internet]. 2001 Feb. Available from: www.rbm.who.int/
196. Zheng T, Holford T, Mayne S, et al. DDE and DDT in breast adipose tissue and risk of female breast cancer. Am J Epidemiol. 1999;150:453-8.
197. Rogan WJ. Pollutants in breast milk. Arch Ped Adol Med. 1996;150:81-90.
198. Gammon MD, Wolf MS, Neugut AI, et al. Environmental toxins and breast cancer on Long Island. II.Organochlorine compound levels in blood. Cancer Epidemiol Biomarkers Prev. 2002;11:677-85.
199. Robison AK, Sirbasku DA, Stancel GM. DDT supports the growth of an estrogen-responsive tumor. Toxicol Lett. 1985;27:109-13.
200. Scribner JD, Mottet NK. DDT acceleration of mammary gland tumors induced in the male Sprague-Dawley rat by 2-acetamidophenanthrene. Carcinogenesis. 1981;2:1235-9.
201. Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer. 1994;74(5):1601-6.
202. Woolcott CG, Aronson KJ, Hanna WM, et al. Organochlorines and breast cancer risk by receptor status, tumor size and grade (Canada). Cancer Causes Control. 2001;12:395-404.
203. Robinson PE, Mack GA, Remmers J, et al. Trends of PCB, hexachlorobenzene, and benzene hexachloride levels in the adipose tissue of the U.S. population. Environ Res. 1990;53:175-92.
204. Hagmar L, Wallin E, Vessby B, et al. Intra-individual variations and time trends 1991-2001 in human serum levels of PCB, DDE, and hexchlorobenzene. Chemosphere. 2006;64:1507-13.
205. Choi AL, Levy JI, Dockery DW, et al. Does living near a Super-fund site contribute to higher polychlorinated biphenyl (PCB) exposure? Environ Health Persp. 2006;114:1092-8.
206. Connor K, Ramamoorthy K, Moore M, et al. Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: Structure-activity relationships. Toxicol App Pharmacol. 1997;145:111-23.
207. Braathen M, Mortensen AS, Sandvik M, et al. Estrogenic effects of selected hydroxy polychlorinated biphenyl congeners in primary culture of Atlantic salmon (Salmo salar) hepatocytes. Arch Environ Contam Toxicol. 2009;56:111-122.
208. Charlier CJ, Albert AI, Zhang L, et al. Polychlorinated biphenyls contamination in women with breast cancer. Clin Chim Acta. 2004;347:177-81.
209. Aronson KJ, Miller AB, Woolcott CG, et al. Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:55-63.
210. Decastro BR, Korrick SA, Spengler JD, et al. Estrogenic activity of polychlorinated biphenyls present in human tissue and the environment. Environ Sci Technol. 2006; 40:2819-2825.
211. Muscat JE, Britton JA, Djordjevic MV, et al. Adipose concentrations of organochlorine compounds and breast cancer recurrence in Long Island, New York. Cancer Epidemiol Biomarkers Prev. 2003;12:1474-8.
212. Salehi F, Turner MC, Phillips KP, et al. Review of the etiology of breast cancer with special attention to organochlorines as potential endocrine disruptors. J Toxicol Environ Health - Pt B: Crit Rev. 2008;11:276-300.
213. Laden F, Collman G, Iwamoto K, et al. 1,1-Dichloro-2,2- bis(pchloroophenyl) ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five U.S. studies. J Natl Cancer Inst. 2001;93:768-76.
214. Gierthy JF, Arcaro KF, Floyd M. Assessment of PCB estrogenicity in a human breast cancer cell line. Chemosphere. 1997;34:1495-1505.
215. Andersson PL, Blom A, Johannisson A, et al. Assessment of PCBs and hydroxylated PCBs as potential xenoestrogens: In vitro studies based on MCF-7 cell proliferation and induction of vitellogenin in primary culture of rainbow trout hepatocytes. Arch Environ Comtam Toxicol . 1999;37:145-50.
216. Hatakeyama M, Matsumura F. Correlation between the activation of Neu tyrosine kinase and promotion of foci formation induced by selected organochlorine compounds in the MCF-7 model system. J Biochem Mol Toxicol. 1999;13(6):296-302.
217. Teitelbaum SL, Gammon MD, Britton JA, et al. Reported residential pesticide use and breast cancer risk on Long Island, New York. Am J Epidemiol. 2006;165: 643-51.
218. O'Connor JC, Plowchalk DR, Van Pelt CS, et al. Role of prolactin in chloro-S-triazine rat mammary tumorigenesis. Drug Chem Toxicol. 2000;23:575-601.
219. U.S. Environmental Protection Agency. Cyanazine (Bladex) terms and conditions of registration. Fed Reg 1999;64:3511-13.
220. U.S. Environmental Protection Agency, Office of Pesticide Programs. Atrazine: third report of the Hazard Identification Assessment Review Committee, 2000 [Internet]. 2007 July 15. Available from: www.epa.gov/pesticides/ factsheets/atrazine-background.htm
221. Villanueva CM, Durand G, CouttÈ MB, et al. Atrazine in municipal drinking water and risk of low birth weight, preterm delivery, and small-for-gestational-age status. Occup Environ Med. 2005;62:400-5.
222. Hua WY, Bennett ER, Maio X-S, et al. Seasonality effects on pharmaceuticals and S-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River. Environ Toxicol Chem. 2006;25:2356-65.
223. Miller S, Sweet C, Depinto J, Hornbuckle K. Atrazine and nutrients in precipitation from the Lake Michigan mass balance study. Environ Sci Technol. 2000;34:55-61.
224. Kettles MA, Browning SR, Prince TS, Hortsman SW. Triazine herbicide exposure and breast cancer incidence: an ecological study of Kentucky counties. Environ Health Persp. 1997;105:1222-7.
225. Hayes T, Haston K, Tsui M, et al. Atrazine-induced hermaphoditism at 0.1ppb in American leopard frogs (Rana pipiens): laboratory and field evidence. Environ Health Persp. 2003;111:568-75.
226. Cooper RL, Stoker TE, Tyrey L, et al. Atrazine disrupts the hypothalamic control of pituitary-ovarian function. Toxicol Sci. 2000;53:297-307.
227. Sanderson JT, Letcher RJ, Heneweer M, et al. Effects of chloro-S-triazine herbicides and metabolites on aromatase activity in various human cell lines and on vitellogenin production in male carp hepatocytes. Environ Health Persp. 2001;109:1027-31.
228. Fan WQ, Yanase T, Morinaga H, et al. Atrazine-induced aromatase expression in SF-1 dependent: implications for endocrine disruption in wildlife and reproductive cancers in humans. Environ Health Rep. 2007;115:720-7.
229. Nabholtz JM. Aromatase inhibitors in the management of early breast cancer. Eur J Surg Oncol. 2008;34:1199-1207.
230. Raynor JL, Enoch RR, Fenton SE. Adverse effects of prenatal exposure to atrazine during a critical period of mammary gland growth. Toxicol Sci. 2005;87:255-66.
231. Siegel BZ. Pesticide hazard assessment project 1981-1984. Honolulu, HI: Pacific Biomedical Research Center, University of Hawaii; 1995. p. 1-63.
232. Maskarinec G, Zhang Y, Takata Y, et al. Trends of breast cancer incidence and risk factor prevalence over 25 years. Breast Cancer Res Treat. 2006;98:45-54.
233. Environmental Working Group. Body burden 2: the pollution in newborns. [Internet] 2005. Available from: www.ewg.org/reports/body burden2.
234. Khanjani N, English DR, Sim MR. An ecological study of organochlorine pesticides and breast cancer in rural Victoria, Australia. Arch Environ Comtam Toxicol. 2006;50:452-61.
235. Cassidy RA, Natarajan S, Vaughan GM. The link between the insecticide heptachlor epoxide, estradiol, and breast cancer. Breast Cancer Res Treat. 2005;90:55-64.
236. Dich J, Zahm SH, Hanberg A, Adami HO. Pesticides (heptachlor) and cancer. Cancer Causes Control. 1997;8:420-43.
237. Agency for Toxic Substances and Disease Registry. Fact sheet [Internet]. 2004 Mar 17. Available from: www.atsdr.cdc.gov/tfacts1.html
238. Hoyer AP, Grandjean P, Jorgensen T, et al. Organochlorine exposure and risk of breast cancer. Lancet. 1998;352(9143):1816-20.
239. Hoyer AP, Jorgensen T, Brock JW, Grandjean P. Organochlorine exposure and breast cancer survival. J Clin Epidemiol. 2000;53:323-30.
240. Andersen HR, Vinggaard AM, Rasmussen TH, et al . Effects of currently used pesticides in assays for estrogenicity, androgenicity, and aromatase activity in vitro. Toxicol App Pharmacol. 2002;179:1-12.
241. Engel LS, Hill DA, Hoppin JA, et al. Pesticide use and breast cancer risk among farmers' wives in the Agricultural Health Study. Am J Epidemiol. 2005;161:121-35.
242. Alexander BH, Mandel JS, Baker BA, et al. Biomonitoring of 2,4-dichlorophenoxyaceetic acid exposure and dose in farm families. Environ Health Persp. 2007;115:370-6.
243. Morris JJ, Seifter E. The role of aromatic hydrocarbons in the genesis of breast cancer. Med Hypoth. 1992;38:177-84.
244. Pliskova M, Vondracek J, Vojtesek B, et al. Deregulation of cell proliferation by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells reflects both genotoxic and nongenotoxic events. Toxicol Sci. 2005;83:246.
245. Kemp MQ, Liu W, Thorne PA, et al. Induction of the transferring receptor gene by benzoapyrene in breast cancer MCF-7 cells: potential as a biomarker of PAH exposure. Environ Mol Mut. 2006;47:518-26.
246. Ralston SL, Coffing SL, Seidel A, et al. Stereoselective activation of dibenzo[a,l]pyrene and its trans-11,12-dihydriol to fjord region 11,12-diol 13,14 epoxides in a human mammary carcinoma MCF-7 cell-mediated V79 cell mutation assay. Chem Res Toxicol. 1997;10:687-93.
247. Gammon MD, Santella RM, Neugut AI, et al. Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev. 2002;11:677-85.
248. Rundle A, Tang D, Hibshoosh H, et al. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis. 2000;21(7):1281-9.
249. Petralia SA, Vena JE, Freudenheim JL, et al. Risk of premenopausal breast cancer in association with occupational exposure to polycyclic aromatic hydrocarbons and benzene. Scand J Work Environ Health. 1999;25:215-21.
250. California Environmental Protection Agency, Air Resources Board. Proposed identification of environmental tobacco smoke as a toxic air contaminant: Appendix A, list of known ETS constituents [Internet]. 2005 June. Available from: www.oehha.ca.gov/air/environmental-tobacco/pdf/app3part b2005.pdf
251. Kilthau GF. Cancer risk in relation to radioactivity in tobacco. Radiol Tech. 1996;67(3):217-22.
252. Hanaoka T, Yamamoto S, Sobue T, et al. Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Disease Study Group: active and passive smoking and breast cancer risk in middle-aged Japanese women. Int J Cancer. 2005;114:317-22.
253. Reynolds P, Hurley S, Goldberg DE, et al. Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst. 2004;96:29-37.
254. Band PR, Le ND, Fang R, Deschamps M. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet. 2002;360:1033-4.
255. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Cigarette smoking and risk of fatal breast cancer. Am J Epidemiol. 1994;139(10):1001-7.
256. Marcus PM, Newman B, Millikan RC, et al. The associations of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk (United States). Cancer Causes Control. 2000;11(3):271-8.
257. Johnson KC, Hu J, Mao Y. Passive and active smoking and breast cancer risk in Canada, 1994-1997: The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control . 2000;11:211-21.
258. Gram IT, Braaten T, Terry PD, et al. Breast cancer among women who started smoking as teenagers. Cancer Epidemiol Biomarkers Prev. 2005;14: 61-6.
259. Slattery ML, Curtin K, Giuliano AR, et al. Active and passive smoking, IL6, ESR1, and breast cancer risk. Breast Cancer Res Treat. 2008;109:101-111.
260. Morabia A, Bernstein M, Heritier S, Khatchartrian N. Relation of breast cancer to active and passive exposure to tobacco smoke. Am J Epidemiol. 1996;143:918-28.
261. California Environmental Protection Agency, Air Resources Board. Proposed identification of environmental tobacco smoke as a toxic air contaminant. Part B: Health effects assessment for environmental tobacco smoke. [Internet] 2005. Available from: ww.arb.ca.gov/toxics/ets/finalreport/finalreport.htm
262. Lee PN, Hamling J. Environmental tobacco smoke exposure and risk of breast cancer in nonsmoking women: A review with meta-analyses. Inhal Toxicol. 2006;18:1053-70.
263. Burridge E. Bisphenol A: surging polycarbonate in Asia has boosted bisphenol A's fortunes. Eur Chem News. 2004;81:17.
264. Matsumoto H, Adachi S, Suzuki Y. Bisphenol A in ambient air particulates responsible for the proliferation of MCF-7 human breast cells and its concentration changes over 6 months. Arch Environ Contam Toxicol. 2005;48:459-66.
265. Rodriguez-Mozaz S, Lopez de Alda M, Barcelo D. Analysis of bisphenol A in natural waters by means of an optical immmunosensor. Water Res. 2005;39: 5071-9.
266. Brotons JA, Olea-Serrano MF, Villalobos M, et al. Xenoestrogens released from lacquer coatings in food cans. Environ Health Persp. 1995;103:608-12.
267. Ikezuki Y, Tsutsumi O, Takai Y, et al. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum Reprod. 2002;17:2839-41.
268. Schonfelder G, Wittfoht W, Hopp H, et al. Parent bisphenol A accumulation in the human maternal-fetal-placental unit. Environ Health Persp. 2002;110:A703-7.
269. Maffini MV, Rubin BS, Sonnenschein C, Soto AM. Endocrine disruptors and reproductive health: the case of bisphenol-A. Mol Cell Endocrinol. 2006;254-255:179-86.
270. Wadia PR, Vandenberg LN, Schaeberle CM, et al. Perinatal bisphenol A exposure increases estrogen sensitivity of the mammary gland in diverse mouse species. Environ Health Persp. 2007;115:80-6.
271. Durando M, Kass L, Piva J, et al. Prenatal bisphenol A exposure induces preneoplastic lesions in the mammary gland in Wistar rats. Environ Health Persp. 2007;115:592-8.
272. Rivas A, Lacroix M, Olea-Serrano F, et al. Estrogenic effect of a series of bisphenol analogues on gene and protein expression in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2002;82:45-53.
273. Welshons WV, Nagel SC, vom Saal FS. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology. 2006;147:S56-9.
274. Watson CS, Bulayeva NN, Wozniak AL, Finnerty CC. Signaling from the membrane via membrane estrogen receptor-alpha: estrogens, xenoestrogens, and phytoestrogens. Steroids. 2005;70:364-71.
275. Wozniak AL, Bulayeva NN, Watson CS. Xenoestrogens at picomolar to nanomolar concentrations trigger membrane estrogen receptor-alpha-mediated Ca2+ fluxes and prolactin release in GH3/B6 pituitary tumor cells. Environ Health Persp. 2005;113:431-9.
276. Iso T, Watanabe T, Iwamoto T, et al. DNA damage caused by bisphenol A and estradiol through estrogenic activity. Biol Pharm Bull. 2006;29:206-10.
277. Slack RJ, Gronow JR, Voulvoulis N. Household hazardous waste in municipal landfills: contaminants in leachate. Sci Total Environ. 2005;337:119-37.
278. Soto AM, Sonnenschein C, Chung KL, et al. The E-SCREEN Assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ Health Persp. 2003;103 (Suppl 7):113-22.
279. Thomas P, Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol. 2006;102:175-9.
280. Moon HJ, Han SY, Shin JH, et al. Gestational exposure to nonylphenol causes precocious mammary gland development in female rat offspring. J Reprod Dev. 2007;53:333-44.
281. Acevedo R, Parnell PG, Villaneuva H, et al. The contribution of hepatic steroid metabolism to serum estradiol and estriol concentrations in nonylphenol treated MMTV neu mice and its potential effects on breast cancer incidence and latency. J Appl Toxicol. 2005;25:339-53.
282. Ionescu JG, Novotny J, Stejskal V, et al. Increased levels of transition metals in breast cancer tissue. Neuroendocrinol Lett. 2006;27(Suppl 1):36-9.
283. Wu HDI, Chou SY, Chen DR, Kuo HW. Differentiation of serum levels of trace elements in normal and malignant breast patients. Biol Trace Elem Res. 2006;113:9-18.
284. Martin MB, Reiter R, Pham T, et al. Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003;144:2425-36.
285. Brama M, Gnessi L, Basciani S, et al. Cadmium induces mitogenic signaling in breast cancer cell by an Eralpha-dependent mechanism. Mol Cell Endocrinol. 2007;264:102-8.
286. Sukocheva OA, Yang Y, Gierthy JF, Seegal RF. Methyl mercury influences growth-related signaling in MCF-7 breast cancer cells. Environ Toxicol. 2005;20:32-44.
287. Rudel RA, Brody JG, Spengler JD, et al. Methods to detect selected potential mammary carcinogens and endocrine disruptors in commercial and residential air and dust samples. J Air Waste Manag Association. 2001;51(4):499-513.
288. Kato K, Silva MJ, Reidy JA, et al. Mono(2-ethyl-5-hydroxyhexyl) phthalate and mono-(2-ethyl-5-oxhexyl) phthalate as biomarkers for human exposure assessment to di-(2-ethylhexyl) phthalate. Environ Health Persp. 2003;112:327-30.
289. Foster PM. Disruption of reproductive development in male rat offspring following in utero exposure to phthalate esters. Int J Androl. 2005;29:140-7.
290. Latini G, Del Vecchio A, Massaro M, et al. Phthalate exposure and male infertility. Toxicology. 2006;226:90-8.
291. Swan SH, Main KM, Liu F, et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Persp. 2005;113:1056-61.
292. Jobling S, Reynolds T, White R, et al. A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Environ Health Persp. 1995;103:582-7.
293. Kang SC, Lee BM. DNA methylation of estrogen receptor agene by phthalates. J Toxicol Environ Health Part A. 2005;68:1995-2003.
294. Kim IY, Han SY, Moon A. Phthalates inhibit tamoxifen-induced apoptosis in MCF-7 human breast cancer cells. J Toxicol Environ Health. 2004;67:2025-35.
295. Lovekamp-Swan T, Davis BJ. Mechanisms of phthalate ester toxicity in female reproductive system. Environ Health Persp. 2003;111:139-45.
296. Jiang JT, Ma L, Yuan L, et al. Study on developmental abnormalities in hypospadiac male rats induced by maternal exposure to di-n-butyl phthalate (DBP). Toxicology. 2007;232:286-93.
297. Borch J, Axelstad M, Vinggaard AM, Dalgaard M. Mechanisms underlying the anti-androgenic effects of diethylhexyl phthalate in fetal rat testis. Toxicology. 2006;223:144-55.
298. Fang H, Tong W, Branham WS, Moland, et al. Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol. 2003;16:1338-58.
299. Cox DG, Blanche H, Pearce CL, et al. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort (BCP3). Breast Cancer Res. 2006;8:R54.
300. Darbre PD, Aljarrah A, Miller WR, et al. Concentrations of parabens in human breast tumours. J Appl Toxicol. 2004;24:5-13.
301. Rastogi SC, Schouten A, Dekruijf N, Weijland JW. Contents of methylparaben, ethylparaben, propylparaben, butylparaben and benzylparaben in cosmetic products. Contact Dermatitis. 1995;32:28-30.
302. Ye X, Bishop AM, Reidy JA, et al. Parabens as urinary biomarkers of exposure in humans. Environ Health Persp. 2006;114:1843-6.
303. Byford JR, Shaw LE, Drew MGB, et al. Oestrogenic activity of parabens in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol. 2002;80:49-60.
304. Hayden CG, Roberts MS, Benson HA. Systemic absorption of sunscreen after topical application. Lancet. 1997;350:853-64.
305. Schlumpf M, Cotton B, Conscience M, et al. In vitro and in vivo estrogenicity of UV screens. Environ Health Persp. 2001;109(3):239-44.
306. Heneweer M, Muusse M, van den Berg M, et al. Additive estrogenic effects of mixtures of frequently used UV filters on pS2-gene transcription in MCF-7 cells. Toxicol App Pharmacol. 2005;208:170-7.
307. Brand RM, McMahon L, Jendrzejewski JL, Charron AR. Transdermal absorption of the herbicide 2,4-dichlorophenoxyacetic acid is enhanced by both ethanol consumption and sunscreen application. Food Chem Toxicol. 2007;45:93-7.
308. Hanrahan C. CRS Report for Congress: RS20142: The European Union's ban on hormone-treated meat [Internet]. 2007. Available from: www.ncseonline.org/NLE/ CRSreports/Agriculture/ag-63.cfm
309. Eaton ML. Ethics analysis applied to Monsanto and the labeling of rbST. In: Ethics and the Business of Bioscience. Palo Alto, CA:Stanford University Press.pp. 70-105.
310. Outwater JL, Nicholson A, Barnard N. Dairy products and breast cancer: the IGF-1, estrogen and bGH hypothesis. Med Hypoth. 1997;48:453-61.
311. Hankinson S, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor 1 and risk of breast cancer. Lancet. 1998;351:1393-6.
312. Daxenberger, A, Bernhard BH, Sauerwein H. Increased milk levels of insulin-like growth factor 1 (IGF-1) for the identification of bovine somatotropin (bST) treated cows. The Analyst. 1998;123:2429-35.
313. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-1 and breast cancer. Int J Cancer. 2000;88:828-832.
314. Allen NE, Roddam AW, Allen DS, et al. A prospective study of serum insulin-like growth factor-I (IGF-1), IGF-II, IGF-binding protein-3 and breast cancer risk. Brit J Cancer. 2005;92:1283-7.
315. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:699-704.
316. Ciftci K, Su J, Trovitch PB. Growth factors and chemotherapeutic modulation of breast cancer cells. J Pharm Pharmacol. 2003;55:1135-41.
317. Furstenberger G, Morant R, Senn HJ. Insulin-like growth factors and breast cancer. Onkologie. 2003;26:290-4.
318. Holly J. Insulin-like growth factor 1 and new opportunities for cancer prevention. Lancet. 1998;351:1373-5.
319. Macaulay VM. Insulin-like growth factors and cancer. Brit J Cancer. 1998;65:311-20.
320. Resnicoff M, Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 1995;55:2463-9.
321. Xian C. Degradation of IGF-1 in the adult rat gastrointestinal tract is limited by a specific antiserum or the dietary protein casein. J Endocrinol. 1995;146:215-25
322. Leffers H, Naesby M, Vendelbo B, et al. Oestrogenic potencies of zeranol, oestradiol, diethylstilbestrol, bisphenol-A and genistein: implications for exposure assessment of potential endocrine disrupters. Hum Reprod. 2001;16:1037-45.
323. Liu S, Kulp SK, Sugimoto Y, et al. Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents. Breast Cancer Res Treat. 2002;71:21-35.
324. Liu S, Lin YC. Transformation of MCF-10A human breast epithelial cells by zeranol and estradiol-17β. Breast J. 2004;10:514-21.
325. Davis S. Benzene: CEH marketing research report abstract. Chemical Industries Newsletter [Internet]. 2006 Sept. Available from: www.sriconsulting.com/CEH/Public/Reports/452.0000/
326. National Toxicology Program. Eleventh report on carcinogens. National Institute of Environmental Health Sciences. National Institutes of Health [Internet]. 2005. Available from: http://ntp.niehs.nih.gov/ntp.niehs.nih.gov/ ntp/roc/eleventh/profiles/s019benz.pdf
327. IARC.Benzene.Iarc Monog Eval Carcinog Risk Chem Hum. 1987;Suppl 7:120-2.
328. Petralia SA, Chow W-H, McLaughlin J, et al. Occupational risk factors for breast cancer among women in Shanghai. Am J Ind Med. 1998;34:477-83.
329. Rennix CP, Quinn MM, Amoroso PJ, et al. Risk of breast cancer among enlisted Army women occupationally exposed to volatile organic compounds. Am J Ind Med. 2005;48:157-67.
330. Shaham J, Gurvich R, Goral A, Czernisk A. The risk of breast cancer in relation to health habits and occupational exposures. Am J Ind Med. 2006;49:1021-30.
331. Huff JE, Haseman JK, DeMarini DM, et al. Multiple-site carcinogenicity of benzene in Fisher 344 rats and B6C3F1 mice. Environ Health Persp. 1989;82:125-63.
332. Houle CD, Ton TV, Clayton N, et al. Frequent p53 and H-ras mutations in benzene- and ethylene oxide-induced mammary gland carcinomas from B6C3F1 mice. Toxicol Pathol. 2006;34:752-62.
333. Labreche, FP, Goldberg, MS. Exposure to organic solvents and breast cancer in women: a hypothesis. Am J Ind Med. 1997;32(1):1-14.
334. U.S. Environmental Protection Agency (EPA), Envirosense. Cleaning agents and cosmetics manufacturers [Internet]. 1996. Available from: es.epa.gov/techinfo/facts/cleaning.html.
335. Wolff MS. Occupationally derived chemicals in breast milk. Am J Ind Med. 1983;4:259-81.
336. Chang YM, Tai CF, Lin RS, et al. A proportionate cancer morbidity ratio study of workers exposed to chlorinated organic solvents in Taiwan. Industrial Health. 2003;41:77-87.
337. McElvenney DM, Darnton AJ, Hodson JT, et al. Cancer among current and former workers at National Semiconductor (UK) LTD, Greenock: results of an investigation by the Health and Safety Executive. Norwich, UK: Her Majesty's Stationary Office. 2001.
338. Hansen J. Breast cancer risk among relatively young women employed in solvent-using industries. Am J Ind Med. 1999;36:43-7.
339. Cantor KP, Stewart, PA, Brinton LA, Dosemeci M. Occupational exposures and female breast cancer mortality in the United States. J Occup Environ Med. 1995;37(3):336-48.
340. Weiderpass E, Pukkala E, Kauppinen T, et al. Breast cancer and occupational exposures in women in Finland. Am J Ind Med. 1999;36:48-53.
341. Wennborg H, Yuen J, Axelsson G, et al. Mortality and cancer incidence in biomedical laboratory personnel in Sweden. Am J Ind Med. 1999;35:382-9.
342. Belli S, Comba P, De Santis M, et al. Mortality study of workers employed by the Italian National Institute of Health, 1960-1989. Scand J Work Environ Health. 1992;18:64-7.
343. Walrath J, Li FP, Hoar SK, et al. Causes of death among female chemists. Am J Public Health. 1985;15:883-5.
344. Wang FI, Kuo ML, Shun CT, et al. Chronic toxicity of a mixture of chlorinated alkanes and alkenes in ICR mice. J Toxicol Environ Health, Part A. 2002;65:279-91.
345. National Toxicology Program. Eleventh report on carcinogens. National Institute of Environmental Health Sciences. National Institutes of Health [Internet]. 2005. Available from: ntpserver. niehs.nih.gov ntp.niehs.nih.gov/ ntp/roc/eleventh/profiles/s186viny.pdf
346. IARC (International Agency for Research on Cancer) 1987. Vinyl Chloride. IARC Summary & Evaluation, Suppl. 7.[Internet]. Available from:http://www.inchem.org/documents/iarc/suppl7/vinylchloride.html
347. Chiazze L Jr., Ference LD. Mortality among PVC fabricating employees. Environ Health Persp. 1981;41:137-43.
348. Infante PF, Pesak J. A historical perspective of some occupationally related diseases of women. J Occup Med. 1994;36:826-31.
349. Agency for Toxic Substances and Disease Registry (ATSDR). Public health statement for vinyl chloride, CAS#75-01-4:. [Internet]. 1997. Available from: http://www.atsdr.cdc.gov/toxprofiles/phs20.html.
350. U.S. Environmental Protection Agency. Health Assessment of 1,3-Butadiene. [Internet]. 2003. Available from: cfpub.epa.gov/ncea/cfm/ recordisplay.cfm? deid=54499
351. National Toxicology Program. Eleventh report on carcinogens. National Institute of Environmental Health Sciences. National Institutes of Health [Internet]. 2005. Available from: ntpserver. niehs.nih.gov ntp.niehs.nih.gov/ ntp/roc/eleventh/profiles/s025buta.pdf
352. Melnick RL, Sills RC, Portier CJ, et al. Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3- butadiene) in F344/N rats and B6C3F1 mice and comparison of doseresponse with 1,3-butadiene in mice. Carcinogenesis. 1999;20:867-78.
353. National Toxicology Program (NTP), U.S. Department of Health and Human Services Toxicology and carcinogenesis studies of 1,3-butadiene (CAS No. 106-99-0) in B6C3F1 mice (inhalation studies). NTP TR 434, NIH Pub. No. 93-3165. Research Triangle Park: NC. 1993.
354. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for ethylene oxide. U.S. Public Health Service, U.S. Department of Health and Human Services, Atlanta, GA. 1990.
355. National Toxicology Program. Eleventh report on carcinogens. National Institute of Environmental Health Sciences. National Institutes of Health [Internet]. 2005. Available from: ntpserver. niehs.nih.gov ntp.niehs.nih.gov/ ntp/roc/eleventh/profiles/s085ethy.pdf
356. Steenland K, Whelan E, Deddens J, et al. Ethylene oxide and breast cancer incidence in a cohort study of 7,576 women. Cancer Causes Control. 2003;14:531-9.
357. Adam A, Bardo H, Adany R. Increased genotoxic susceptibility of breast epithelial cells to ethylene oxide. Mut Res. 2005;585:120-6.
358. DeBruin LS, Pawliszyn JB, Josephy PD. Detection of monocyclic aromatic amines, possible mammary carcinogens, in human milk. Chem Res Toxicol. 1999;12:78-82.
359. DeBruin LS, Josephy PD. Perspectives on the chemical etiology of breast cancer. Environ Health Persp. 2002;110(Suppl 1):119-28.
360. National Toxicology Program. Chemicals associated with site-specific tumor induction in mammary gland [Internet]. 2003. Available from: ntp-server.niehs.nih.gov/htdocs/sites/MAMM.html
361. Layton DW, Bogen KT, Knize MG, et al. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis. 1995;16:39-52.
362. Steck SE, Gaudet MM, Eng SM, et al. Cooked meat and risk of breast cancer: lifetime versus recent dietary intake. Epidemiology. 2007;18:373-82.
363. Thompson PA, DeMarini DM, Kadlubar FF, et al. Evidence for the presence of mutagenic arylamines in human breast milk and DNA adducts in exfoliated breast ductal epithelial cells. Environ Mol Mut. 2002;39:134-42.
364. Turesky RJ. Formation and biochemistry of carcinogenic heterocyclic aromatic amines in cooked meats. Toxicol Lett. 2007;168:219-27.
365. Gooderham NJ, Creton S, Lauber SN, Zhu H. Mechanisms of action of the carcinogenic heterocyclic amine PhIP. Toxicol Lett. 2006;168:269-77.
366. Environmental Protection Agency (EPA). Understanding radiation: gamma rays [Internet]. 2005. Available from: www.epa.gov/radiation/understand/gamma. htm
367. National Toxicology Program. Eleventh report on carcinogens. National Institute of Environmental Health Sciences. National Institutes of Health [Internet]. 2005. Available from: ntpserver. niehs.nih.gov ntp.niehs.nih.gov/ ntp/roc/eleventh/profiles/s097zird.pdf
368. Environmental Protection Agency. Federal radiation protection guidance for exposure of the general public. Notice, Federal Register December 23, 1994.
369. Brenner DJ, Doll R, Goodhead DT, et al. Cancer risks attributable to low doses of ionizing radiation. Proc Natl Acad Sci. 2003;100(24):13761-6.
370. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources and effects of ionizing radiation: UNSCEAR 1993 report to the General Assembly, with scientific annexes. 1993. p. 636.
371. National Radiological Protection Board (Britain). Risk of radiation-induced cancer at low doses and low-dose rates for radiation protection purposes. Documents of the NRPB. 1995;6(1):25.
372. National Research Council. Biologic effects of ionizing radiation VII: Health risks from exposure to low levels of ionizing radiation. Washington DC: National Academy of Science. 2005. 373. Goldberg Z, Lehnert BE. Radiation-induced effects in unirradiated cells: a review and implications in cancer. Int J Oncol. 2003;21:337-49.
373. Morgan WF. Non-targeted and delayed effects of exposure to ionizing radiation: II. Radiation-induced genomic instability and bystander effects in vivo, castogenic factors and transgenerational effects. Radiat Res. 2003;159:581-96.
374. Wright EG. Radiation-induced genomic instability: manifestations and mechanisms. Int J Low Radiat. 2004;1: 231-41.
375. Tsai KK, Chuang EY, Little JB, Yuan ZM. Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment. Cancer Res. 2005;65:6734-44.
376. Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment: tumorogenesis and therapy. Nat Rev Cancer. 2005;5:867-75.
377. Little JB. Genomic instability and radiation. J Radiolog Protect. 2003;23:173-81.
378. Murray D, MccEwan AJ. Radiobiology of systemic radiation therapy. Cancer Biother Radiopharm. 2007;22:1-22.
379. Turnbull C, Mirugaesu N, Eeles R. Radiotherapy and genetic predisposition to breast cancer. Clin Oncol. 2006;18:257-67.
380. Andrieu N, Easton DF, Chang-Claud J, et al. Effect of chest X-rays on the risk of breast cancer among BRCA 1/2 mutation carriers in the International BRCA 1/2 Carrier Cohort Study: a report from EMBRACE, GEGNNEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol. 2006;24:3361-6.
381. Calaf GM, Hei TK. Establishment of a radiation- and estrogen-induced breast cancer model. Carcinogenesis. 2000;21:769-76.
382. Segaloff A, Maxfield WS. The synergism between radiation and estrogen in the production of mammary cancer in the rat. Cancer Res. 1971;31:166-8.
383. Segaloff A, Pettigrew HM. Effect of radiation dosage on the synergism between radiation and estrogen in the production of mammary cancer in the rat. Cancer Res. 1974;38:3445-52.
384. Land CD. Radiation and breast cancer risk. Prog Clin Biol Res. 1997;396:115-24.
385. Ron E, Ikeda T, Preston DL, Tokuoka S. Male breast cancer incidence among atomic bomb survivors. J Natl Cancer Inst. 2005;97:603-5.
386. Gofman JW. Preventing breast cancer: The story of a major, proven, preventable cause of this disease. 2nd ed. San Francisco: CNR Book Division, Committee for Nuclear Responsibility; 1996.
387. MacKenzie I. Breast cancer following multiple fluoroscopies. Brit J Cancer. 196;19:1-8.
388. Mattsson A, Ruden BI, Palmgren J, Rutqvist LE. Dose-and time-response for breast cancer risk after radiation therapy for benign breast disease. Brit J Cancer. 1995;72:1054-61.
389. Shore RE, Hildreth N, Woodard E, et al. Breast neoplasms in women given X-ray therapy for acute postpartum mastitis. J Natl Cancer Inst. 1986;77:689-96.
390. Lundell M, Mattsson A, Karlsson P, et al. Breast cancer risk after radiotherapy in infancy: a pooled analysis of two Swedish cohorts of 17,202 infants. Radiat Res. 1999;151:626-32.
391. Bhatia S, Robison LI, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334:745-51.
392. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin's disease. J Am Med Assoc. 2003;290:465-75.
393. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386-94.
394. Wahner-Roedler DL, Nelson DF, Croghan IT, et al. Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin's lymphoma: Mayo Clinic experience. Mayo Clin Proc. 2003;87:708-15.
395. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003;95:971-80.
396. Guibout C, Adjadj E, Rubino C, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol. 2005;23:197-204.
397. Wahner-Roedler DL, Petersen IA. Risk of breast cancer and breast cancer characteristics in women after treatment for Hodgkin's lymphoma. Drugs Today. 2004;40:865-79.
398. Horwich A, Swerdlow AJ. Secondary primary breast cancer after Hodgkin's disease. Brit J Cancer. 2004;90:294-8.
399. El-Gamal H, Bennett RG. Increased breast cancer risk after radiotherapy for acne among women with skin cancer. J Am Acad Derm. 2006;55:981-9.
400. Morin-Doody M, Freedman DM, Alexande BH, et al. Breast cancer incidence in U.S. radiologic technologists. Cancer. 2006;106:2707-15.
401. Simon SL, Weinstock RM, Doody MM, et al. Estimating historical radiation doses to a cohort of U.S. radiologic technologists. Radiat Res. 2006;166:174-92.
402. Ballard T, Lagorio S, De Angelis G, Verdecchia A. Cancer incidence and mortality among flight personnel: a meta-analysis. Aviat Space Environ Med. 2000;71:216-24.
403. Gofman JW. Radiation from medical procedures in the pathogenesis of cancer and ischemic heart disease: Dose-response studies with physicians per 100,000 population. San Francisco: CNR Book Division, Committee for Nuclear Responsibility; 1999.
404. Bailar JC III. Mammography: a contrary view. Ann Intern Med. 1976;84:77-84.
405. Huda W, Nickoloff Hl, Boone JM. Overview of patient dosimetry in diagnostic radiology in the USA for the past 50 years. Med. Physics 2008;35:5713-5728.
406. National Cancer Institute. Radiation risks and pediatric computed tomography (CT): a guide for healthcare providers. [Internet]. 2002. Available from: www.cancer.gov
407. Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993;328:1587-91.
408. Early Breast Cancer Trialists' Collaborative Group. Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomized trials. Lancet. 2000;355:1757-70.
409. Roychoudhuri R, Evans H, Robinson D, Moller H. Radiation-induced malignancies following radiotherapy for breast cancer. Brit J Cancer. 2004;91:868-72.
410. Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2285-92.
411. Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer. 2001;92:532-6.
412. IARC. Non-Ionizing Radiation. IARC. Monog Eval Carcinog Risk Chem Hum. 2002; 80. Available at http://monographs.iarc.fr/ENG/Monographs/vol80/volume80. pdf
413. NIEHS Working Group Report. Assessment of health effects from exposure to power-line frequency electric and magnetic fields. Research Park Triangle:National Institute of Environmental Health Sciences of the National Institutes of Health. 1998.
414. BioInitiative Working Group. BioInitiative Report. 2007. Available at: http://www.bioinitiative.org/report/index.htm
415. Erren TC. A meta-analysis of epidemiologic studies of electric and magnetic fields and breast cancer in women and men. Bioelectromagnetics. 2001;Suppl 5:S105-19.
416. McElroy JA, Egan KM, Titus-Ernstoff L, et al. Occupational exposure to electromagnetic field and breast cancer risk in a large, population-based, case-control study in the United States. J Occup Environ Med. 2007;49:266-74.
417. Peplonska B, Stewart P, Szeszenia-Dabrowska N, et al. Occupation and breast cancer risk in Polish women: a population-based case-control study. Am J Ind Med. 2007;50:97-111.
418. Kliukiene J, Tynes T, Anderson A. Follow-up of radio and telegraph operators with exposure to electromagnetic fields and risk of breast cancer. Eur J Cancer Prev. 2003;12:301-7.
419. Dosemeci M, Blair A. Occupational cancer mortality among women employed in the telephone industry. J Occup Med. 1994;36;1204-9.
420. Coogan PF, Clapp RW, Newcomb PA, et al. Occupational exposure to 60-hertz magnetic fields and risk of breast cancer in women. Epidemiology. 1996;7:459-64.
421. Kliukiene J, Tynes T, Andersen A. Residential and occupational exposures to 50-Hz magnetic fields and breast cancer in women: a population-based study. Am J Epidemiol. 2004;159:852-61.
422. Feychting M, Forssen U, Rutqvist LE, Ahlbom A. Magnetic fields and breast cancer in Swedish adults residing near high-voltage power lines. Epidemiology. 1998;9:392-7.
423. Zhu K, Hunter S, Payne-Wilks K, et al. Use of electric bedding devices and risk of breast cancer in African American women. Am J Epidemiol. 2003;158:798-806.
424. Milham S. A cluster of male breast cancer in office workers. Am J Ind Med. 2004;46:86-7.
425. Loomis DP. Cancer of breast among men in electrical occupations (letter). Lancet. 1992;339:1482-3.
426. Tynes T, Andersen A, Langmark F. Incidence of cancer in Norwegian workers potentially exposed to electromagnetic fields. Am J Epidemiol. 1992;136:81-8.
427. Matanoski GM, Breysse PN, Elliott EA. Electromagnetic field exposure and male breast cancer. Lancet. 1991;337:737.
428. Fedrowitz M, Kamino K, Loscher W. Significant differences in the effects of magnetic field exposure on 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in two substrains of Sprague-Dawley rats. Cancer Res. 2004;64:243-51.
429. Stevens RG, Davis S, Thomas DB, et al. Electric power, pineal function, and the risk of breast cancer. FASEB J. 1992;6:853-60.
430. Nie K, Henderson A. MAP kinase activation in cells exposed to a 60Hz electromagnetic field. J Cell Biochem. 2003;90:1197-1206.
431. Sanchez-Barcelo EJ, Cos S, Mediavilla D, et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res. 2005;38:217-22.
432. Blask DE, Wilson ST, Zalatan F. Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Res. 1997;57:1909-14.
433. Hensen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology. 2001;12:74-7.
434. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93:1557-62.
435. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst. 2001;93:1563-8.
436. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst. 2005;97:1084-7.
437. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulfoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2008;100:898-105.
438. Nudelman J, Taylor B, Evans N, et al. Policy and research recommendations emerging from the scientific evidence connecting environmental factors and breast cancer. Int J Occup Environ Health. 2008.